Emerald Advisers LLC Has $28.39 Million Holdings in Nektar Therapeutics $NKTR

Emerald Advisers LLC boosted its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 2.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 394,604 shares of the biopharmaceutical company’s stock after acquiring an additional 10,262 shares during the period. Emerald Advisers LLC’s holdings in Nektar Therapeutics were worth $28,392,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NKTR. BNP Paribas Financial Markets increased its holdings in shares of Nektar Therapeutics by 93.8% in the third quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 210 shares in the last quarter. Deutsche Bank AG lifted its holdings in shares of Nektar Therapeutics by 0.8% during the 4th quarter. Deutsche Bank AG now owns 90,743 shares of the biopharmaceutical company’s stock valued at $3,837,000 after purchasing an additional 743 shares in the last quarter. Bayforest Capital Ltd lifted its holdings in shares of Nektar Therapeutics by 51.3% during the 4th quarter. Bayforest Capital Ltd now owns 2,541 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 862 shares in the last quarter. FNY Investment Advisers LLC grew its position in shares of Nektar Therapeutics by 70.6% in the 3rd quarter. FNY Investment Advisers LLC now owns 2,602 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 1,077 shares during the period. Finally, XTX Topco Ltd grew its position in shares of Nektar Therapeutics by 22.0% in the 4th quarter. XTX Topco Ltd now owns 7,196 shares of the biopharmaceutical company’s stock valued at $304,000 after purchasing an additional 1,299 shares during the period. 75.88% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Jonathan Zalevsky sold 5,681 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $70.00, for a total value of $397,670.00. Following the transaction, the insider owned 9,756 shares in the company, valued at approximately $682,920. This represents a 36.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Howard W. Robin sold 10,000 shares of the stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $60.32, for a total value of $603,200.00. Following the transaction, the chief executive officer owned 65,045 shares in the company, valued at approximately $3,923,514.40. This trade represents a 13.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 21,862 shares of company stock valued at $1,379,205. Company insiders own 2.50% of the company’s stock.

Nektar Therapeutics Stock Performance

Shares of Nektar Therapeutics stock opened at $68.32 on Tuesday. The business’s 50 day simple moving average is $67.35 and its 200 day simple moving average is $64.01. Nektar Therapeutics has a 52-week low of $21.02 and a 52-week high of $109.00. The firm has a market cap of $2.31 billion, a PE ratio of -8.11 and a beta of 1.13.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($1.58) by ($0.24). Nektar Therapeutics had a negative return on equity of 85.40% and a negative net margin of 284.18%.The business had revenue of $10.86 million for the quarter, compared to analyst estimates of $10.69 million. As a group, equities research analysts predict that Nektar Therapeutics will post -9.45 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. HC Wainwright raised their target price on shares of Nektar Therapeutics from $165.00 to $185.00 and gave the stock a “buy” rating in a report on Monday, April 20th. Jefferies Financial Group reiterated a “buy” rating on shares of Nektar Therapeutics in a report on Wednesday, April 22nd. BTIG Research increased their price objective on shares of Nektar Therapeutics from $151.00 to $178.00 and gave the stock a “buy” rating in a research report on Monday, April 20th. Wall Street Zen upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, May 17th. Finally, Wedbush cut their price objective on shares of Nektar Therapeutics from $95.00 to $80.00 and set a “neutral” rating on the stock in a research report on Monday, May 11th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $149.62.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.